The full name of the contract, which, due to the limited number of characters, did not fit into section II.1.1) of the notice, reads: Successive supply of medicinal products containing the active substances: prednisone (Encorton 5 mg; Encorton 10 mg; Encorton 20 mg) and sulfamethoxazole + trimethoprim (Biseptol 120 mg; Biseptol 480 mg) for a non-commercial clinical trial.
Part/Package 1 - Medicinal products containing the active substance prednisone (Encorton 5 mg, Encorton 10 mg, Encorton 20 mg)1) Part/Package No. 1 - Medicinal products containing the active substance prednisone (Encorton 5 mg, Encorton 10 mg, Encorton 20 mg) tabl., according to the summary of product characteristics:
a) prednizone (Encorton) 5 mg – 200 on. x 20 tabl.
b) prednizone (Encorton) 10 mg – 200 on. x 20 tabl.
c) prednizone (Encorton) 20 mg – 200 on. x 20 tabl.
Part/Package 2 - Medicinal products containing the active substance sulfamethoxazole + trimethoprim (Biseptol 120 mg; Biseptol 480 mg) tabl1) Part/Package No 2 - Medicinal products containing the active substance sulfamethoxazole + trimethoprim (Biseptol 120 mg; Biseptol 480 mg) tabl.:
a) sulfametoksazole + trimethoprim (Biseptol 120 mg) – 750 op. x 20 tabl.
b) sulfametoksazole + trimetoprim (Biseptol 480 mg) – 260 op. x 20 tabl.